Business
Curaleaf International Launches a Range of Medical Cannabis Products in Australia
Curaleaf International Launches a Range of Medical Cannabis Products in Australia Canad...
About this update from Curaleaf Holdings, Inc.
[{"type":"text","content":"\n\n\n\n Curaleaf International Launches a Range of Medical Cannabis Products in Australia\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n LONDON\n \n\n ,\n \n\n May 15, 2025\n \n\n /CNW/ -- Curaleaf International, part of Curaleaf Holdings, Inc. (TSX:CURA) a leading international provider of medical cannabis products, today announced the launch of Curaleaf branded products in\n \n Australia\n \n . This announcement marks the expansion of Curaleaf's presence in one of the world's fastest growing medical cannabis markets and underscores its commitment to local collaboration, clinical integrity, and patient care.\n \n\n\n\n\n\n\n\n\n The initial product offering, comprising four cannabis flower strains, will be distributed via Canngea, a licensed Australian manufacturer and wholesaler with a wealth of experience in medical cannabis. This partnership supports Curaleaf's vision to be the world's leading cannabis company by consistently delivering superior products and services.\n \n\n Over the coming months, patients and healthcare professionals in\n \n Australia\n \n can look forward to a broader portfolio and further innovative solutions offered by Curaleaf, including precision-dosed inhalation formats and popular strains already widely prescribed across the UK,\n \n Germany\n \n , and other key European markets.\n \n\n\n Juan Martinez\n \n , Head of Curaleaf International, commented: \"Entering the Australian market is a significant milestone in our global strategy to expand access to high-quality, evidence-backed cannabis medicines. We're committed to supporting Australian patients and healthcare professionals with reliable, consistent products and the backing of one of the industry's most advanced supply chains.\"\n \n\n\n Boris Jordan\n \n , Chairman and CEO of Curaleaf, added: \"\n \n Australia\n \n is an exciting and rapidly evolving market, expected to surpass\n \n $1 billion\n \n in annual sales next year, and this launch is a positive step forward in our strategy to extend our position as the global leader in cannabis. We're br...